Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery
SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation solutions for synthetic biology at SynBioBeta 2023 which is being held May 23-25 in Oakland, California.
Telesis Bio will present in two speaker sessions: Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio and David Brown, Ph.D., Director R&D, RNAimmune will present “Beyond COVID: Leveraging synthetic biology to advance the potential of mRNA-based vaccines” on Tuesday May 23rd. RNAimmune will showcase the application of the BioXp platform for accelerating their vaccine discovery workflows. Daniel Gibson, Ph.D., CTO and Co-founder will present “Streamlining molecular biology workflows throughout biologics discovery” on Wednesday, May 24th. His presentation will focus on the BioXp platform technology and updates on expanding capabilities in synthetic biology, library preparation for NGS and application of on-demand automated synthesis with SOLA EDS technology.
The award winning BioXp® system and associated BioXp® De novo and Select synthesis kits as well as NGS library prep kits provide a complete automated solution for accelerating many synthetic biology and genomics workflows throughout discovery. The system assists researchers in optimizing their discovery process by enabling sequence to screening in days, rather than weeks or months with alternative methods.
Telesis Bio will also present in two poster sessions at the conference: Qi Zhang, Ph.D. Scientist, R&D will present “Automated solutions for addressing mRNA synthesis bottlenecks in therapeutics discovery” and David Weiss, Director of Product Management will present “Construction & Sequence Verification of Custom Genomes: Using the BioXp to streamline design to test workflow” to showcase application of the NGS library preparation kits for plasmid sequencing on the BioXp platform.
For more information on Telesis Bio at SynBiobeta visit: https://telesisbio.com/synbiobeta-2023/
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 12, 2023, as amended on May 1, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
Vice President of Investor Relations
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock5.6.2023 23:30:00 CEST | Press release
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the closing of its private placement of redeemable convertible preferred stock and warrants resulting in initial gross proceeds of $28.0 million to Telesis Bio. The warrants issued in the private placement will provide Telesis Bio with approximately $46.2 million in additional gross proceeds if they are cash exercised. The financing was led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company’s Chief Executive Officer and Founder, Todd R. Nelson, PhD. The Company also announced the appointment of Paul Meister, a partner at Novalis LifeSciences LLC, to the Company’s board of directors immediately following the closing. Please refer to the Company’s Form 8-K to be filed with the Securities and Exchang
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress5.6.2023 22:01:00 CEST | Press release
All 7 out of 7 eligible patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter’s Transformation (RT), responded to treatment (Objective Response Rate of 100%)1 GLPG5201 showed no cytokine release syndrome (CRS) higher than grade 2, or immune effector cell-associated neurotoxicity syndrome (ICANS)2 A functionally closed, automated manufacturing platform for cell therapies at the point-of-care will be shown at the Galapagos booth A.103at the EHA 2023 congress Mechelen, Belgium; 5 June 2023,22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and willpresent previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany. “Patients who develop rrCLL and become resistant to new agents have a very poor prognosis and a significant high
Hoylu AB: Publicerar årsredovisning för 20225.6.2023 21:15:00 CEST | Pressemelding
Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2022 bifogas detta pressmeddelande och finns tillgänglig på bolagets hemsida: (https://www.hoylu.com/investor-relations/financial-reports/). För mer information kontakta: Truls Baklid, CEO, +47 924 38 900 Email: email@example.com Karl Wiersholm, CFO, +1 425 829 2316 Email: firstname.lastname@example.org Om Hoylu Hoylus uppdrag är att ge distribuerade team möjlighet att samarbeta enkelt och sömlöst samtidigt som de alltid håller sig synkroniserade. Hoylus Adaptive Workspaces™ hjälper företag såväl stora som små att driva projekt, program och initiativ över olika tidszoner och kontinenter med samma engagemang och tydlighet som om alla arbetade i samma rum. För mer information: www.hoylu.com Kortnamn: Hoylu Marknadsplats: Nasdaq First North Growth Stockholm Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550; email@example.com Publicering Informationen lämnades, genom ovanstående kontaktpersons försorg för offentliggörande den 5 ju
Hoylu AB: Publishes its Annual Report for 20225.6.2023 21:15:00 CEST | Press release
Hoylu AB (publ) announced today that the Annual Report for 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information contact: Truls Baklid, CEO, +47 924 38 900 Email: firstname.lastname@example.org Karl Wiersholm, CFO, +1 425 829 2316 Email: email@example.com About Hoylu Hoylu’s visual collaboration technology empowers distributed teams to translate ideas into actions. Large enterprises as well as small and medium companies rely on Hoylu to run projects, programs, and initiatives across time zones and continents as seamlessly as when working in the same room. For more information: www.hoylu.com Try Hoylu for free: https://app.hoylu.com/ Ticker symbol: Hoylu Marketplace: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550, firstname.lastname@example.org Publication The information was submitted for publication, through the agency of the contact person set out above, at 21:15 CE
Nokia Corporation: Repurchase of own shares on 05.06.20235.6.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 5 June 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 05.06.2023 Espoo, Finland – On 5 June 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL308,5933.85CEUX48,4053.86AQEU4,7293.86TQEX3,3733.87Total365,1003.86 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and en